Pan-mutant FLT3 Inhibitor
Acute Myeloid Leukemia (AML) and other hematologic tumors
Pre-clinicalActive
Key Facts
Indication
Acute Myeloid Leukemia (AML) and other hematologic tumors
Phase
Pre-clinical
Status
Active
Company
About KinSea Lead Discovery
KinSea Lead Discovery is an early-stage biotech leveraging the unique biodiversity of the Arctic Ocean to discover novel small-molecule therapeutics. Its lead program targets pan-mutant FLT3 for acute myeloid leukemia, with a compound that has reportedly passed animal proof-of-concept. The company is a spin-off from leading Norwegian academic institutions and is backed by European venture capital, having secured seed financing and a significant grant from Innovation Norway.
View full company profile